drugset / Trial / NCT05711940

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940

Phase 3 Active not recruiting 572 enrolled COMPASS Pathways
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Timeline

Start
2023-02-14
Primary completion
2026-02
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 1 mg
Subject Psilocybin Other / unclassified 10 mg
Subject Psilocybin Other / unclassified 25 mg

Indications

No indication recorded.